AC133 Expression Profile
| Primary Cells and Cell Lines . | Protein Detected by FACS Staining . | Primary Cells and Cell Lines . | Protein Detected by FACS Staining . | ||
|---|---|---|---|---|---|
| . | . | . | . | . | . |
| Primary cells | |||||
| Nucleated red blood cells | − | ||||
| Lymphocytes | − | ||||
| Monocytes | − | ||||
| Granulocytes | − | ||||
| Platelets | − | ||||
| Fetal thymocytes | − | ||||
| Fetal splenocytes | − | ||||
| CD34+ cells from all tissues | + | ||||
| PHA-activated PBMCs | − | ||||
| Baboon CD34+† | − | ||||
| NZB + LPR mouse splenocytes | − | ||||
| NZB + LPR mouse thymocytes | − | ||||
| NZB + LPR mouse hepatocytes | − | ||||
| Hematopoietic cell lines | |||||
| 8402*† | |||||
| T-cell line | − | ||||
| JM | |||||
| T-cell line | − | ||||
| Jurkat* | |||||
| T-cell line | − | ||||
| HPB-ALL* | |||||
| T-ALL | − | ||||
| Molt-4 | |||||
| T-ALL | − | ||||
| HUT-78 | |||||
| Cutaneous T-cell lymphoma | − | ||||
| HEL.92.1.7* | |||||
| Erythroleukemia | − | ||||
| K562* | |||||
| Erythroleukemia | − | ||||
| 8866 | |||||
| EBV-transformed B-cell line | − | ||||
| IM-9 | |||||
| EBV-transformed B-cell line | − | ||||
| Daudi* | |||||
| EBV-transformed B-cell line | − | ||||
| Raji | |||||
| EBV-transformed B-cell line | − | ||||
| HS-Sultan | |||||
| EBV-transformed B-cell line | − | ||||
| T.5.1 | |||||
| EBV-transformed B-cell line | − | ||||
| BJAB | |||||
| North American Burkitt's lymphoma | − | ||||
| KG1† | |||||
| AML | − | ||||
| KG1a*† | |||||
| AML | − | ||||
| HL-60 | |||||
| Promyelocytic leukemia | − | ||||
| RPMI-8226 | |||||
| Myeloma | − | ||||
| U937 | |||||
| Histiocytic lymphoma | − | ||||
| Nonhematopoietic cell lines | |||||
| 134H* | |||||
| Glioblastoma | − | ||||
| AZ676 | |||||
| Carcinosarcoma, breast | − | ||||
| BT474 | |||||
| Ductal carcinoma, breast | − | ||||
| BT549 | |||||
| Ductal carcinoma, breast | − | ||||
| T47D | |||||
| Ductal carcinoma, breast | − | ||||
| BT20 | |||||
| Carcinoma, breast | − | ||||
| Du4475† | |||||
| Metastatic cutaneous nodule, breast carcinoma | − | ||||
| MCF-7 | |||||
| Adenocarcinoma, breast | − | ||||
| H4* | |||||
| Neuroglioma | − | ||||
| SK-N-MG* | |||||
| Neuroepithelioma, metastasis to supraorbital area | − | ||||
| SK-N-SH* | |||||
| Neuroblastoma, metastasis to bone marrow | − | ||||
| IMR-32 | |||||
| Neuroblastoma | − | ||||
| WERI-Rb-1 | |||||
| Retinoblastoma | + | ||||
| Y79 | |||||
| Retinoblastoma | + | ||||
| CACL74-36 | |||||
| Melanoma | − | ||||
| HT1080 | |||||
| Fibrosarcoma | − | ||||
| CC90 | |||||
| Diploid fibroblast | − | ||||
| CC93 | |||||
| Diploid fibroblast | − | ||||
| CC95 | |||||
| Diploid fibroblast | − | ||||
| HT29 | |||||
| Adenosarcoma, colon | − | ||||
| COLO 205 | |||||
| Adenosarcoma, colon | − | ||||
| SK HEP-1 | |||||
| Adenocarcinoma, liver | − | ||||
| Chang Liver | |||||
| Hela markers | − | ||||
| HUVEC† | |||||
| Umbilical vein endothelial cells | − | ||||
| NT2 | |||||
| Teratocarcinoma line | + | ||||
| hNT | |||||
| Neuron cell derived from NT2 | − | ||||
| Primary Cells and Cell Lines . | Protein Detected by FACS Staining . | Primary Cells and Cell Lines . | Protein Detected by FACS Staining . | ||
|---|---|---|---|---|---|
| . | . | . | . | . | . |
| Primary cells | |||||
| Nucleated red blood cells | − | ||||
| Lymphocytes | − | ||||
| Monocytes | − | ||||
| Granulocytes | − | ||||
| Platelets | − | ||||
| Fetal thymocytes | − | ||||
| Fetal splenocytes | − | ||||
| CD34+ cells from all tissues | + | ||||
| PHA-activated PBMCs | − | ||||
| Baboon CD34+† | − | ||||
| NZB + LPR mouse splenocytes | − | ||||
| NZB + LPR mouse thymocytes | − | ||||
| NZB + LPR mouse hepatocytes | − | ||||
| Hematopoietic cell lines | |||||
| 8402*† | |||||
| T-cell line | − | ||||
| JM | |||||
| T-cell line | − | ||||
| Jurkat* | |||||
| T-cell line | − | ||||
| HPB-ALL* | |||||
| T-ALL | − | ||||
| Molt-4 | |||||
| T-ALL | − | ||||
| HUT-78 | |||||
| Cutaneous T-cell lymphoma | − | ||||
| HEL.92.1.7* | |||||
| Erythroleukemia | − | ||||
| K562* | |||||
| Erythroleukemia | − | ||||
| 8866 | |||||
| EBV-transformed B-cell line | − | ||||
| IM-9 | |||||
| EBV-transformed B-cell line | − | ||||
| Daudi* | |||||
| EBV-transformed B-cell line | − | ||||
| Raji | |||||
| EBV-transformed B-cell line | − | ||||
| HS-Sultan | |||||
| EBV-transformed B-cell line | − | ||||
| T.5.1 | |||||
| EBV-transformed B-cell line | − | ||||
| BJAB | |||||
| North American Burkitt's lymphoma | − | ||||
| KG1† | |||||
| AML | − | ||||
| KG1a*† | |||||
| AML | − | ||||
| HL-60 | |||||
| Promyelocytic leukemia | − | ||||
| RPMI-8226 | |||||
| Myeloma | − | ||||
| U937 | |||||
| Histiocytic lymphoma | − | ||||
| Nonhematopoietic cell lines | |||||
| 134H* | |||||
| Glioblastoma | − | ||||
| AZ676 | |||||
| Carcinosarcoma, breast | − | ||||
| BT474 | |||||
| Ductal carcinoma, breast | − | ||||
| BT549 | |||||
| Ductal carcinoma, breast | − | ||||
| T47D | |||||
| Ductal carcinoma, breast | − | ||||
| BT20 | |||||
| Carcinoma, breast | − | ||||
| Du4475† | |||||
| Metastatic cutaneous nodule, breast carcinoma | − | ||||
| MCF-7 | |||||
| Adenocarcinoma, breast | − | ||||
| H4* | |||||
| Neuroglioma | − | ||||
| SK-N-MG* | |||||
| Neuroepithelioma, metastasis to supraorbital area | − | ||||
| SK-N-SH* | |||||
| Neuroblastoma, metastasis to bone marrow | − | ||||
| IMR-32 | |||||
| Neuroblastoma | − | ||||
| WERI-Rb-1 | |||||
| Retinoblastoma | + | ||||
| Y79 | |||||
| Retinoblastoma | + | ||||
| CACL74-36 | |||||
| Melanoma | − | ||||
| HT1080 | |||||
| Fibrosarcoma | − | ||||
| CC90 | |||||
| Diploid fibroblast | − | ||||
| CC93 | |||||
| Diploid fibroblast | − | ||||
| CC95 | |||||
| Diploid fibroblast | − | ||||
| HT29 | |||||
| Adenosarcoma, colon | − | ||||
| COLO 205 | |||||
| Adenosarcoma, colon | − | ||||
| SK HEP-1 | |||||
| Adenocarcinoma, liver | − | ||||
| Chang Liver | |||||
| Hela markers | − | ||||
| HUVEC† | |||||
| Umbilical vein endothelial cells | − | ||||
| NT2 | |||||
| Teratocarcinoma line | + | ||||
| hNT | |||||
| Neuron cell derived from NT2 | − | ||||
Cell lines were maintained as described, and single-cell suspensions were prepared in PBS containing 0.5% BSA and 0.1% sodium azide. Following staining with AC133PE or control antibodies, cells were washed and fixed in 1% paraformaldehyde in PBS before flow cytometric analysis.
Tested negative for AC133 expression following PMA activation.
CD34+ but AC133−.